Related Experiment Video
Updated: Jun 20, 2026

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
[Urinary toxicological screening: analytical interference between niflumic acid and cannabis]
A Boucher1, P Vilette, N Crassard
1Centre d'évaluation et d'information sur la pharmacodépendance (CEIP), 162 avenue Lacassagne, Lyon cedex 03, France.
Unlabelled:
One case of analytical interference between cannabis and niflumic acid resulting in a false-positive screening in a 3-year-old girl is described.
Case Report:
The child was hospitalized because of behavioral disturbances of unknown origin. The only noteworthy finding in her medical history was a drug treatment including suppositories of niflumic acid, started 5 days before. The initial urinary toxicological screening was positive for cannabinoids, but the child's parents strongly denied the exposure. Another analysis was performed by the same laboratory on the same urine sample using chromatography and confirmed the absence of any cannabinoids, while clearly identifying the presence of niflumic acid.
Comments:
Immunoanalysis for toxicological analysis has various limitations that must be known. False-positive results of the urinary screening for cannabis in patients treated with niflumic acid are well recognized although seldom reported. All usual screening tests are not concerned by this ill-explained interference with niflumic acid and all formulations can be involved except transcutaneous formulations. Because of the wide use of this nonsteroidal anti-inflammatory drug, particularly in pediatric patients, it is important to know that this type of interference can occur with various screening tests for cannabis so that misleading conclusions can be avoided.
Related Concept Videos
Drug toxicity: Drug–Drug Interaction
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Urine Studies II: Urine Culture and Sensitivity Test
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

